Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | FFAR2 | O15552 | 6/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | GCK | P35557 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2136080 | 0.88 | ALOX15 (0.41) | MAOANPC1RAB9ACCR2MAOB | |
| SCHEMBL2136387 | 0.82 | AHR (0.42) | AHRMAOANPC1RAB9ACCR2 | |
| SCHEMBL2707575 | 0.74 | PRKAB2 (0.38) | CREBBP | |
| SCHEMBL2138644 | 0.74 | AHR (0.42) | AHRMAOANPC1RAB9ACCR2 | |
| SCHEMBL2136340 | 0.74 | FUCA1 (0.36) | — | |
| SCHEMBL2138480 | 0.73 | AHR (0.42) | AHRMAOANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2136182 | 0.73 | L3MBTL1 (0.44) | AHRNPC1CCR2FFAR2 | |
| SCHEMBL2139189 | 0.73 | AHR (0.42) | AHRMAOANPC1RAB9ACCR2 | |
| SCHEMBL2139572 | 0.71 | AHR (0.40) | AHRMAOAMAOBGCK | |
| SCHEMBL2138898 | 0.71 | AHR (0.40) | AHRMAOANPC1RAB9ACCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101137-A1 | NOVEL THIOPHENECARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101137-A1 | NOVEL THIOPHENECARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | GCK, GCKR, HK2 | AHR 3039/4885MAOA 1773/4885NPC1 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.